Journal of International Oncology››2022,Vol. 49››Issue (1): 1-11.doi:10.3760/cma.j.cn371439-20210621-00001
Received:2021-06-21Revised:2021-11-21Online:2022-01-08Published:2022-01-17
"
| 分型 | 适应证 | 剂量及分次 | 参考来源 |
|---|---|---|---|
| 周围型 | 小病灶(<2 cm),GTV距胸壁>1 cm | 34 Gy/1 F | RTOG 0915 |
| PTV不紧贴胸壁时 | 5460 Gy/3 Fa | RTOG 0618和RTOG 0236 | |
| 6066 Gy/3 F | 参考文献[
|
||
| 45 Gy/3 F | 参考文献[
|
||
| PTV紧邻或与胸壁重叠时 | 4860 Gy/45 Fb | RTOG 0915/参考文献[
|
|
| 中央型 | PTV在中央或毗邻中央区内,但在超中央区外 | 5060 Gy/5 F | RTOG 0813 |
| 50 Gy/4 F或70 Gy/10 F | 参考文献[
|
||
| 60 Gy/8 F | 参考文献[
|
||
| PTV超中央型的区域内 | 5060 Gy/810 Fc | 参考文献[
|
"
| PTV(cm3) | 处方剂量体积与 PTV体积比 |
50%处方剂量体积与 PTV体积比,R50% |
PTV外2 cm处最大剂量, D2 cm(Gy) |
肺20 Gy所占体积百分比, V20 Gy(%) |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 偏差 | 偏差 | 偏差 | 偏差 | ||||||||
| 无 | 可接受 | 无 | 可接受 | 无 | 可接受 | 无 | 可接受 | ||||
| 1.8 | <1.2 | <1.5 | <5.9 | <7.5 | <50.0 | <57.0 | <10 | <15 | |||
| 3.8 | <1.2 | <1.5 | <5.5 | <6.5 | <50.0 | <57.0 | <10 | <15 | |||
| 7.4 | <1.2 | <1.5 | <5.1 | <6.0 | <50.0 | <58.0 | <10 | <15 | |||
| 13.2 | <1.2 | <1.5 | <4.7 | <5.8 | <50.0 | <58.0 | <10 | <15 | |||
| 22.0 | <1.2 | <1.5 | <4.5 | <5.5 | <54.0 | <63.0 | <10 | <15 | |||
| 34.0 | <1.2 | <1.5 | <4.3 | <5.3 | <58.0 | <68.0 | <10 | <15 | |||
| 50.0 | <1.2 | <1.5 | <4.0 | <5.0 | <62.0 | <77.0 | <10 | <15 | |||
| 70.0 | <1.2 | <1.5 | <3.5 | <4.8 | <66.0 | <86.0 | <10 | <15 | |||
| 95.0 | <1.2 | <1.5 | <3.3 | <4.4 | <70.0 | <89.0 | <10 | <15 | |||
| 126.0 | <1.2 | <1.5 | <3.1 | <4.0 | <73.0 | <91.0 | <10 | <15 | |||
| 163.0 | <1.2 | <1.5 | <2.9 | <3.7 | <77.0 | <94.0 | <10 | <15 | |||
"
"
"
"
"
"
"
"
"
| OAR | 1 F | 3 F | 4 F | 5 F |
|---|---|---|---|---|
| 脊髓 | 14 Gy | 18 Gy(6 Gy/F) | 26 Gy(6.5 Gy/F) | 30 Gy(6 Gy/F) |
| 食管 | 15.4 Gy | 27 Gy(9 Gy/F) | 30 Gy(7.5 Gy/F) | 105%PTV处方剂量 |
| 臂丛神经 | 17.5 Gy | 24 Gy(8 Gy/F) | 27.2 Gy(6.8 Gy/F) | 32 Gy(6.4 Gy/F) |
| 心脏/心包 | 22 Gy | 30 Gy(10 Gy/F) | 34 Gy(8.5 Gy/F) | 105%PTV处方剂量 |
| 大血管 | 37 Gy | NS | 49 Gy(12.25 Gy/F) | 105%PTV处方剂量 |
| 气管及近端支气管 | 20.2 Gy | 30 Gy(10 Gy/F) | 34.8 Gy(8.7 Gy/F) | 105%PTV处方剂量 |
| 肺 | V7<1 500 cm3 | V10.5<1 500 cm3 | V11.6<1 500 cm3 | V12.5<1 500 cm3 |
| V7.4<1 000 cm3 | V11.4<1 000 cm3 | V12.4<1 000 cm3 | V13.5<1 000 cm3 | |
| 肋骨 | 30 Gy | 30 Gy(10 Gy/F) | 40 Gy(10 Gy/F) | NS |
| 皮肤 | 26 Gy | 24 Gy(8 Gy/F) | 36 Gy(9 Gy/F) | 32 Gy(6.4 Gy/F) |
| 胃 | 12.4 Gy | NS | 27.2 Gy(6.8 Gy/F) | NS |
| 肝脏 | 17.1 Gy(5.7 Gy/Fx) | 19.2 Gy(4.8 Gy/Fx) | 21 Gy(4.2 Gy/Fx) |
"
"
"
"
"
"
| [1] | Postmus PE, Kerr KM, Oudkerk M, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2017, 28(suppl_4): iv1-iv21. DOI: 10.1093/annonc/mdx222. doi:10.1093/annonc/mdx222 |
| [2] | Ramon RP, Hisao A, William DT, et al. Lung//Amin MB, Edge SB, Greene FL, eds. AJCC Cancer Staging Manual. Eighth Edition[M]. Chicago, USA: Springer, 2017: 431-456. DOl: 10.1007/978-3-319-40618-3_36. doi:10.1007/978-3-319-40618-3_36 |
| [3] | Howlader N, Noone AM, Krapcho M, et al. SEER cancer statistics review, 1975-2016[EB/OL]. [2020-04-09]. https://seer.cancer.gov/csr/1975_2016/. |
| [4] | Palma D, Visser O, Lagerwaard FJ, et al. Impact of introducing ste-reotactic lung radiotherapy for elderly patients with stage Ⅰ non-small-cell lung cancer: a population-based time-trend analysis[J]. J Clin Oncol, 2010, 28(35):5153-5159. DOI: 10.1200/jco.2010.30.0731. doi:10.1200/jco.2010.30.0731 |
| [5] | Timmerman RD, Hu C, Michalski J, et al. Long-term results of RTOG 0236: a phase Ⅱ trial of stereotactic body radiation therapy (SBRT) in the treatment of patients with medically inoperable stage Ⅰ non-small cell lung cancer[J]. Int J Radiat Oncol Biol Phys, 2014, 90(suppl_1):S30. DOI: 10.1016/j.ijrobp.2014.05.135. doi:10.1016/j.ijrobp.2014.05.135 |
| [6] | Murray P, Franks K, Hanna GG. A systematic review of outcomes following stereotactic ablative radiotherapy in the treatment of early-stage primary lung cancer[J]. Br J Radiol, 2017, 90(1071):20160732. DOI: 10.1259/bjr.20160732. doi:10.1259/bjr.20160732 |
| [7] | Modh A, Rimner A, Williams E, et al. Local control and toxicity in a large cohort of central lung tumors treated with stereotactic body radiation therapy[J]. Int J Radiat Oncol Biol Phys, 2014, 90(5):1168-1176. DOI: 10.1016/j.ijrobp.2014.08.008. doi:10.1016/j.ijrobp.2014.08.008 |
| [8] | Mangona VS, Aneese AM, Marina O, et al. Toxicity after central versus peripheral lung stereotactic body radiation therapy: a propensity score matched-pair analysis[J]. Int J Radiat Oncol Biol Phys, 2015, 91(1):124-132. DOI: 10.1016/j.ijrobp.2014.08.345. doi:10.1016/j.ijrobp.2014.08.345 |
| [9] | Chang JY, Mehran RJ, Feng L, et al. Stereotactic ablative radiothe-rapy for operable stage Ⅰ non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery[J]. Lancet Oncol, 2021, 22(10):1448-1457. DOI: 10.1016/s1470-2045(21)00401-0. doi:10.1016/s1470-2045(21)00401-0 |
| [10] | Steffen IG, Wust P, Rühl R, et al. Value of combined PET/CT for radiation planning in CT-guided percutaneous interstitial high-dose-rate single-fraction brachytherapy for colorectal liver metastases[J]. Int J Radiat Oncol Biol Phys, 2010, 77(4):1178-1185. DOI: 10.1016/j.ijrobp.2009.06.047. doi:10.1016/j.ijrobp.2009.06.047 |
| [11] | 中华医学会放射肿瘤治疗学分会, 中国抗癌协会肿瘤放射治疗学专业委员会, 中国医师协会放射治疗医师分会. 早期非小细胞肺癌立体定向放疗中国专家共识(2019版)[J]. 中华肿瘤杂志, 2020, 42(7):522-530. DOI: 10.3760/cma.j.cn112152-20200116-00039. doi:10.3760/cma.j.cn112152-20200116-00039 |
| [12] | Timmerman R, McGarry R, Yiannoutsos C, et al. Excessive toxicity when treating central tumors in a phase Ⅱ study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer[J]. J Clin Oncol, 2006, 24(30):4833-4839. DOI: 10.1200/JCO.2006.07.5937. doi:10.1200/JCO.2006.07.5937pmid:17050868 |
| [13] | Lagerwaard FJ, Haasbeek CJ, Smit EF, et al. Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage Ⅰ non-small-cell lung cancer[J]. Int J Radiat Oncol Biol Phys, 2008, 70(3):685-692. DOI: 10.1016/j.ijrobp.2007.10.053. doi:10.1016/j.ijrobp.2007.10.053 |
| [14] | Baumann P, Nyman J, Hoyer M, et al. Outcome in a prospective phase Ⅱ trial of medically inoperable stage Ⅰ non-small-cell lung cancer patients treated with stereotactic body radiotherapy[J]. J Clin Oncol, 2009, 27(20):3290-3296. DOI: 10.1200/JCO.2008.21.5681. doi:10.1200/JCO.2008.21.5681pmid:19414667 |
| [15] | Chang JY, Li QQ, Xu QY, et al. Stereotactic ablative radiation therapy for centrally located early stage or isolated parenchymal recurrences of non-small cell lung cancer: how to fly in a "no fly zone"[J]. Int J Radiat Oncol Biol Phys, 2014, 88(5):1120-1128. DOI: 10.1016/j.ijrobp.2014.01.022. doi:10.1016/j.ijrobp.2014.01.022 |
| [16] | Zhao Y, Khawandanh E, Thomas S, et al. Outcomes of stereotactic body radiotherapy 60 Gy in 8 fractions when prioritizing organs at risk for central and ultracentral lung tumors[J]. Radiat Oncol, 2020, 15(1):61. DOI: 10.1186/s13014-020-01491-w. doi:10.1186/s13014-020-01491-w |
| [17] | Raman S, Yau V, Pineda S, et al. Ultracentral tumors treated with stereotactic body radiotherapy: single-institution experience[J]. Clin Lung Cancer, 2018, 19(5):e803-e810. DOI: 10.1016/j.cllc.2018.06.001. doi:10.1016/j.cllc.2018.06.001 |
| [18] | Meng MB, Wang HH, Zaorsky NG, et al. Risk-adapted stereotactic body radiation therapy for central and ultra-central early-stage inoperable non-small cell lung cancer[J]. Cancer Sci, 2019, 110(11):3553-3564. DOI: 10.1111/cas.14185. doi:10.1111/cas.14185 |
| [19] | Tekatli H, Haasbeek N, Dahele M, et al. Outcomes of hypofractionated high-dose radiotherapy in poor-risk patients with "ultracentral" non-small cell lung cancer[J]. J Thorac Oncol, 2016, 11(7):1081-1089. DOI: 10.1016/j.jtho.2016.03.008. doi:10.1016/j.jtho.2016.03.008pmid:27013408 |
| [20] | Lindberg K, Bergström P, Brustugun OT, et al. OA24.05 the Nordic HILUS-trial-first report of a phase Ⅱ trial of SBRT of centrally located lung tumors[J]. J Thorac Oncol, 2017, 12(1):S340. DOI: 10.1016/j.jtho.2016.11.369. doi:10.1016/j.jtho.2016.11.369 |
| [21] | Chaudhuri AA, Tang C, Binkley MS, et al. Stereotactic ablative radiotherapy (SABR) for treatment of central and ultra-central lung tumors[J]. Lung Cancer, 2015, 89(1):50-56. DOI: 10.1016/j.lungcan.2015.04.014. doi:10.1016/j.lungcan.2015.04.014pmid:25997421 |
| [22] | Lenglet A, Campeau MP, Mathieu D, et al. Risk-adapted stereotactic ablative radiotherapy for central and ultra-central lung tumours[J]. Radiother Oncol, 2019, 134:178-184. DOI: 10.1016/j.radonc.2019.01.035. doi:S0167-8140(19)30063-5pmid:31005213 |
| [23] | Tambe NS, Fryer A, Marsden JE, et al. Determination of clinically appropriate flattening filter free (FFF) energy for treating lung SABR using treatment plans and delivery measurements[J]. Biomed Phys Eng Express, 2016, 2(6):065016. DOI: 10.1088/2057-1976/2/6/065016. doi:10.1088/2057-1976/2/6/065016 |
| [24] | Li J, Galvin J, Harrison A, et al. Dosimetric verification using monte carlo calculations for tissue heterogeneity-corrected conformal treatment plans following RTOG 0813 dosimetric criteria for lung cancer stereotactic body radiotherapy[J]. Int J Radiat Oncol Biol Phys, 2012, 84(2):508-513. DOI: 10.1016/j.ijrobp.2011.12.005. doi:10.1016/j.ijrobp.2011.12.005 |
| [25] | Hurkmans CW, Cuijpers JP, Lagerwaard FJ, et al. Recommen-dations for implementing stereotactic radiotherapy in peripheral stage ⅠA non-small cell lung cancer: report from the Quality Assurance Working Party of the randomised phase Ⅲ ROSEL study[J]. Radiat Oncol, 2009, 4:1. DOI: 10.1186/1748-717X-4-1. doi:10.1186/1748-717X-4-1pmid:19138400 |
| [26] | Ueki N, Matsuo Y, Togashi Y, et al. Impact of pretreatment interstitial lung disease on radiation pneumonitis and survival after ste-reotactic body radiation therapy for lung cancer[J]. J Thorac Oncol, 2015, 10(1):116-125. DOI: 10.1097/JTO.0000000000000359. doi:10.1097/JTO.0000000000000359 |
| [27] | Bahig H, Filion E, Vu T, et al. Severe radiation pneumonitis after lung stereotactic ablative radiation therapy in patients with interstitial lung disease[J]. Pract Radiat Oncol, 2016, 6(5):367-374. DOI: 10.1016/j.prro.2016.01.009. doi:10.1016/j.prro.2016.01.009 |
| [28] | Forquer JA, Fakiris AJ, Timmerman RD, et al. Brachial plexopathy from stereotactic body radiotherapy in early-stage NSCLC: dose-limiting toxicity in apical tumor sites[J]. Radiother Oncol, 2009, 93(3):408-413. DOI: 10.1016/j.radonc.2009.04.018. doi:10.1016/j.radonc.2009.04.018 |
| [29] | Lindberg K, Grozman V, Lindberg S, et al. Radiation-induced brachial plexus toxicity after SBRT of apically located lung lesions[J]. Acta Oncol, 2019, 58(8):1178-1186. DOI: 10.1080/0284186X.2019.1601255. doi:10.1080/0284186X.2019.1601255pmid:31066326 |
| [30] | Song SY, Choi W, Shin SS, et al. Fractionated stereotactic body radiation therapy for medically inoperable stage Ⅰ lung cancer adjacent to central large bronchus[J]. Lung Cancer, 2009, 66(1):89-93. DOI: 10.1016/j.lungcan.2008.12.016. doi:10.1016/j.lungcan.2008.12.016 |
| [31] | Abelson JA, Murphy JD, Loo BW, et al. Esophageal tolerance to high-dose stereotactic ablative radiotherapy[J]. Dis Esophagus, 2012, 25(7):623-629. DOI: 10.1111/j.1442-2050.2011. 01295.x. doi:10.1111/j.1442-2050.2011.01295.xpmid:22168251 |
| [32] | Evans JD, Gomez DR, Amini A, et al. Aortic dose constraints when reirradiating thoracic tumors[J]. Radiother Oncol, 2013, 106(3):327-332. DOI: 10.1016/j.radonc.2013.02.002. doi:10.1016/j.radonc.2013.02.002 |
| No related articles found! |
| Viewed | ||||||
| Full text |
|
|||||
| Abstract |
|
|||||
